Haploidentical Stem Cell Transplant With Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL

Overview

This is a single center Phase I trial of a new haploidentical stem cell transplant regimen intended to assess safety. Two groups of patients are planned: patients with lymphoma and patients with multiple myeloma.

SparkCures ID 1198
Trial Phase Phase 1
Enrollment 30 Patients
Treatments
Tags
Trial Sponsors
  • Cedars-Sinai Medical Center
Trial Collaborators
  • Teva Pharmaceuticals
  • Miltenyi Biomedicine GmbH
NCT Identifier

NCT03524235

Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

The following criteria is provided for health care professionals.

US Trial Locations

Please visit the ClinicalTrials.gov page for historical site information.

View Centers